evipedia.ai ← Back to Review

Audit: QRS - L-Arginine for Health & Longevity

Audit conducted on 15/07/2026 02:17 using AI4L / Opus 4.8

Iterations

Summary

Items Count
Total 91
Passed 81
Failed 0
N/A 10
Pass Rate 100.00%
  • Total = Passed + Failed + N/A
  • Pass Rate = Passed / (Passed + Failed) × 100
  • N/A items are excluded from the pass rate calculation

1. General Rules

# Description Result Comments
1.1 Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. 🟢 All doses, magnitudes, contraindications, interactions, and biomarker targets trace to the ER.
1.2 Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. 🟢 Speculative tiers and “where present” qualifiers mirror ER caution.
1.3 The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). 🟢 Contraindications retain “avoid” strength; benefits retain tier strength.
1.4 The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. 🟢 Contraindications, interactions, benefits, risks, monitoring all sourced from matching ER sections.
1.5 PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. 🟢 No citations, NCT IDs, or expert names introduced in QRS.
1.6 The QRS does not introduce new attributions. 🟢 No attributions present.

2. Focus, Tone & Audience

# Description Result Comments
2.1 The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. 🟢 Objective, evidence-graded tone matches the ER.
2.2 The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging 🟢 Balanced expert/accessible framing throughout.
2.3 The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor 🟢 Presents evidence, not directives.
2.4 The QRS avoids language that implies medical or clinical advice 🟢 Presents protocol facts; footer disclaimer present.
2.5 The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” 🟢 Uses descriptive framing (“Standard for…”, “Preferred over…”).
2.6 The QRS never addresses “the reader” directly — it presents evidence, not guidance 🟢 No second-person address anywhere.
2.7 The QRS is written in plain language, avoiding unnecessary medical jargon 🟢 Plain terms used; technical names limited to biomarker table.
2.8 Information is presented in a concise and very compact manner 🟢 Compact cells, lists, and table.
2.9 It DOES NOT address the reader directly 🟢 No direct address.
2.10 The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. 🟢 Framing suits proactive longevity-focused readers.
2.11 The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. 🟢 Protocol/monitoring detail assumes engaged reader.
2.12 The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. 🟢 Not general-population framing.
2.13 Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. 🟢 Weighting mirrors ER’s tiered assessment.
2.14 The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. 🟢 Uses “Longevity”; no “anti-aging”.
2.15 The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. 🟢 Formal terminology used throughout.

3. Template Integrity

# Description Result Comments
3.1 The following labels and headings on the QRS are fixed and not modified: Card and section headings (“Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”); Gate headings (“Contraindications”, “Key Interactions”); Tier labels (“High”, “Medium”, “Low”, “Speculative”); Table column headers in Monitoring (“Marker”, “Target”, “Why”) 🟢 All fixed headings/labels intact.
3.2 All “…” from the [qrs_template] are present in the the QRS. 🟢 All expected variable spans present.
3.3 Spans that are not addressed in a checklist item are left unchanged 🟢 No unaddressed spans altered.

4. Formatting

# Description Result Comments
4.1 When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” N/A No mapped ER sections are empty; all tiers populated.
4.2 Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. 🟢 Qualitative labels (“Energy and exercise capacity”, etc.) reused verbatim.
4.3 Labels are not paraphrased, abbreviated, or invented. 🟢 Labels preserved.
4.4 The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. 🟢 No emoji; ER “⚠️ Conflicted” markers stripped.
4.5 The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. 🟢 Content condensed to single-page budget.

5. Metadata

# Description Result Comments
5.1 The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. 🟢 Metadata comment at lines 2–14.
5.2 Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. 🟢 Delimited by “—” at lines 3 and 13.
5.3 The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. 🟢 Enclosed in HTML comment.
5.4 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Values trimmed; duration quoted for colon.
5.5 The filename of the source ER is stated as “er_filename: [er_filename]” 🟢 er_filename: l_arginine_2026-0715-0133_Opus_ER.md
5.6 Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” 🟢 qrs_prompt_version: 26.7.02
5.7 Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) 🟢 qrs_creation_date: 2026-0715-0208
5.8 The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” 🟢 qrs_creator_ai_nickname: Opus
5.9 The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) 🟢 “Opus”.
5.10 The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” 🟢 qrs_creator_ai_fullname: Opus 4.8
5.11 The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) 🟢 “Opus 4.8”.
5.12 The filename of the document is stated as “qrs_filename: [filename of this document]” 🟢 qrs_filename: l_arginine_2026-0715-0133_Opus_QRS.html
5.13 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Frontmatter clean and consistent.

6. Page Title & Header

# Description Result Comments
6.1 [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., &amp; for &) 🟢 “L-Arginine for Health & Longevity - Quick Reference Sheet”.
6.2 [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., &amp; for &) 🟢 “L-Arginine for Health & Longevity”.
6.3 [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] 🟢 07/15/2026 from 2026-0715-0208.
6.4 [header_subline_model] is set to [qrs_creator_ai_fullname] 🟢 “Opus 4.8”.
6.5 No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. 🟢 Header limited to date, ER link, and model.

7. At-A-Glance Section

# Description Result Comments
7.1 [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section 🟢 Condenses the ER Conclusion (lines 415–417).
7.2 [at_a_glance] is no longer than 60 words 🟢 55 words.
7.3 Every fact in [at_a_glance] is supported by a distinct passage in the ER. 🟢 Nitric oxide mechanism, BP, erectile, low-cost/limited all in Conclusion.
7.4 It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead 🟢 Plain language; no acronyms.
7.5 It DOES NOT cite specific trials (names, years, sample sizes, p-values) 🟢 No trial citations.
7.6 It DOES NOT cite effect sizes, relative risks, or statistical results 🟢 No statistics; “modest lowering” only.

8. Contraindications

# Description Result Comments
8.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 Sourced from ER lines 290–292.
8.2 [stop_items] represent the Contraindications from the ER 🟢 All six “avoid” populations present.
8.3 Individual [stop_items] are formatted as <li></li> 🟢 Each item is an <li>.
8.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash — these trailing clauses are stripped. Just the key fact. 🟢 Concise; no trailing clauses.
8.5 Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 “within ~90 days”, “eGFR below ~30”, “except under supervision” preserved.
8.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A ER contraindications use no ranking notation.
8.7 If no [stop_items] are present the section is left empty N/A Contraindications are present.

9. Key Interactions

# Description Result Comments
9.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 Sourced from ER lines 274–288.
9.2 [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications 🟢 ED drugs, nitrates, BP meds, potassium drugs, anticoagulants, lysine, vasodilating supplements; no contraindication overlap.
9.3 Individual [caution_items] are formatted as <li></li> 🟢 Each item is an <li>.
9.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash — these trailing clauses are stripped. Just the key fact. 🟢 Concise; only example-drug parentheticals retained.
9.5 Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 Named example drugs preserved for each class.
9.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A ER interactions use no ranking notation.
9.7 If no [caution_items] are present the section is left empty N/A Key Interactions are present.

10. Protocol

# Description Result Comments
10.1 The section is derived from the ER Protocol section 🟢 Sourced from ER Therapeutic Protocol (lines 310–332).
10.2 The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section 🟢 Dose, Schedule, Timing.
10.3 If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A Three actionable aspects are present.
10.4 All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. 🟢 All three cells carry ER-derived content.

11. Time to Effect

# Description Result Comments
11.1 The three sets of [time] items cover the three most important time-to-effect aspects from the ER 🟢 Blood pressure, erectile function, acute blood flow (ER line 356).
11.2 The sets are picked and ordered by the magnitude of the related benefit 🟢 Ordered High→Medium→Low benefit.
11.3 If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A Three time-to-effect aspects are present.
11.4 All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. 🟢 All cells ER-derived.
11.5 If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel N/A ER provides time-to-effect data.

12. Benefits

# Description Result Comments
12.1 The section is derived from the ER Expected Benefits section 🟢 Matches ER Expected Benefits (lines 142–196).
12.2 Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] 🟢 All four tiers populated correctly.
12.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Bare benefit names only.
12.4 Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parentheticals; “⚠️ Conflicted” markers dropped.
12.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. N/A All four tiers have items.

13. Risks

# Description Result Comments
13.1 The section is derived from the ER Potential Risks & Side Effects section 🟢 Matches ER Risks (lines 210–258).
13.2 Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] 🟢 All four tiers populated correctly.
13.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Bare risk names only.
13.4 Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parentheticals retained.
13.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. N/A All four tiers have items.

14. Monitoring

# Description Result Comments
14.1 The section is derived from the ER Monitoring section 🟢 Sourced from ER Monitoring table (lines 380–388).
14.2 All measurable/quantifiable biomarkers from the Monitoring section are listed 🟢 All seven biomarkers with targets present.
14.3 [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. 🟢 Baseline + 4wk/8–12wk + 6–12 month cadence populated (line 681).

15. Qualitative Assessment

# Description Result Comments
15.1 The section is derived from the ER Monitoring section 🟢 From ER qualitative markers (lines 392–395).
15.2 All subjective/qualitative biomarkers from the Monitoring section are listed 🟢 All four qualitative markers present.

Issues 15/07/2026 02:17

Pass rate 100.00%. No issues found.